Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Cellular therapeutic comprised of human cells of the glial lineage”In the company’s words, NCT03887273 on ClinicalTrials.gov
- Tested for
- Transverse Myelitis, Amyotrophic Lateral Sclerosis
- Main trialPhase 1/2
- “This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects with Transverse Myelitis. For each of the dose levels, transplantation of Q-Cells® unilaterally into spinal cord demyelinated lesions will be evaluated. Subjects will be blinded to side of treatment.”In the company’s words, NCT03887273 on ClinicalTrials.gov
- Other names
- glial restricted progenitor cells
Other drugs for Transverse Myelitis
- EculizumabAlexion Pharmaceuticals, Inc. · Phase 3
- SatralizumabRoche · Phase 3
- B001Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- RavulizumabAlexion Pharmaceuticals, Inc. · Phase 3
- VibegronUrovant Sciences GmbH · Phase 2/3
- DivozilimabBiocad · Phase 3
Coming up2
- Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jul 2027 | Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis | |
| Phase 1/2Not yet recruiting | Dec 2028 | Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026